Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11β-hydroxysteroid dehydrogenase type 1

Endocrinology

Volumn 153, Issue 7, 2012, Pages 3236-3248

  Lavery, Gareth G ^a   Zielinska, Agnieszka E ^a   Gathercole, Laura L ^a   Hughes, Beverly ^a   Semjonous, Nina ^a   Guest, Phillip ^a   Saqib, Khalid ^a   Sherlock, Mark ^a   Reynolds, Gary ^a   Morgan, Stuart A ^a   Tomlinson, Jeremy W ^a   Walker, Elizabeth A ^a   Rabbitt, Elizabeth H ^a   Stewart, Paul M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; CORTICOSTERONE; CORTISONE; GLUCOCORTICOID; HYDROCORTISONE; INSULIN; STEROID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORTICOSTEROID METABOLISM; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE SILENCING; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPID DIET; LIVER; LIVER MICROSOME; MALE; METABOLIC DISORDER; METABOLISM; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ALLELES; ANIMALS; BIOLOGICAL MARKERS; CORTISONE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOCORTICOIDS; HYDROCORTISONE; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROSOMES, LIVER; PHENOTYPE;

EID: 84862748339     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1019     Document Type: Article

References (54)

1. Nordlie RC, Foster JD, Lange AJ 1999 Regulation of glucose production by the liver. Annu Rev Nutr 19:379-406 (Pubitemid 29380610)
2. Pilkis SJ, Granner DK 1992 Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol 54:885-909
3. Gathercole LL, Stewart PM 2010 Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes. J Steroid Biochem Mol Biol 122:21-27
4. Friedman TC, Mastorakos G, Newman TD, Mullen NM, Horton EG, Costello R, Papadopoulos NM, Chrousos GP 1996 Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM. Endocr J 43:645-655 (Pubitemid 126447899)
5. Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E, Connell JM 1999 Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 33:1364-1368 (Pubitemid 29282655)
6. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM 2004 11β-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25:831-866 (Pubitemid 39366049)
7. Lavery GG, Walker EA, Draper N, Jeyasuria P, Marcos J, Shackleton CH, Parker KL, White PC, Stewart PM 2006 Hexose-6-phosphate dehydrogenase knock-out mice lack 11β-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation. J Biol Chem 281:6546-6551 (Pubitemid 43847588)
8. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, Mullins JJ 1997 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 94:14924-14929 (Pubitemid 28041476)
9. Morton NM, Holmes MC, Fiévet C, Staels B, Tailleux A, Mullins JJ, Seckl JR 2001 Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 276:41293-41300
10. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ, Seckl JR 2004 Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53:931-938 (Pubitemid 38436604)
11. Wamil M, Battle JH, Turban S, Kipari T, Seguret D, de Sousa Peixoto R, Nelson YB, Nowakowska D, Ferenbach D, Ramage L, Chapman KE, Hughes J, Dunbar DR, Seckl JR, Morton NM 2011 Novel fat depot-specific mechanisms underlie resistance to visceral obesity and inflammation in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 60:1158-1167
12. Bujalska IJ, Hewitt KN, Hauton D, Lavery GG, Tomlinson JW, Walker EA, Stewart PM 2008 Lack of hexose-6-phosphate dehydrogenase impairs lipid mobilization from mouse adipose tissue. Endocrinology 149:2584-2591 (Pubitemid 351574493)
13. Lavery GG, Hauton D, Hewitt KN, Brice SM, Sherlock M, Walker EA, Stewart PM 2007 Hypoglycemia with enhanced hepatic glycogen synthesis in recombinant mice lacking hexose-6-phosphate dehydrogenase. Endocrinology 148:6100-6106 (Pubitemid 350146145)
14. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS 2001Atransgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170 (Pubitemid 33150673)
15. Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinyama H, Sharp MG, Fleming S, Mullins JJ, Seckl JR, Flier JS 2003 Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 112:83-90 (Pubitemid 38056379)
16. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR, Mullins JJ 2004 Metabolic syndrome without obesity: hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 101:7088-7093 (Pubitemid 38596447)
17. Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingström G, Larsson C, Forsgren M, Ashkzari M, Nilsson CE, Fiedler M, Bergqvist E, Ohman B, Björkstrand E, Abrahmsen LB 2003 Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144:4755-4762 (Pubitemid 37378389)
18. Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger JM, Mundt SS, Noonan H, Nunes CN, Olson SH, Pikounis B, Ren N, Robertson N, Schaeffer JM, Shah K, Springer MS, Strack AM, Strowski M, Wu K, Wu T, Xiao J, Zhang BB, Wright SD, Thieringer R 2005 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 202:517-527 (Pubitemid 41186950)
19. Lloyd DJ, Helmering J, Cordover D, Bowsman M, Chen M, Hale C, Fordstrom P, Zhou M, Wang M, Kaufman SA, Véniant MM 2009 Antidiabetic effects of 11β-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis. Diabetes Obes Metab 11:688-699
20. Park JS, Rhee SD, Kang NS, Jung WH, Kim HY, Kim JH, Kang SK, Cheon HG, Ahn JH, Kim KY 2011 Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethano ne (KR-66344). Biochem Pharmacol 81:1028-1035
21. Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, Hollis G, Flores R, Levy R, Williams WV, Seckl JR, Huber R 2010 The 11-β- hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 33:1516-1522
22. Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CR 1995 Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 80:3155-3159
23. Harris HJ, Kotelevtsev Y, Mullins JJ, Seckl JR, Holmes MC 2001 Intracellular regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase (11β-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis: analysis of 11β-HSD-1-deficient mice. Endocrinology 142:114-120 (Pubitemid 32183672)
24. Paterson JM, Holmes MC, Kenyon CJ, Carter R, Mullins JJ, Seckl JR 2007 Liver-selective transgene rescue of hypothalamic-pituitary-adrenal axis dysfunction in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Endocrinology 148:961-966
25. Rogoff D, Ryder JW, Black K, Yan Z, Burgess SC, McMillan DR, White PC 2007 Abnormalities of glucose homeostasis and the hypothalamic-pituitary-adrenal axis in mice lacking hexose-6-phosphate dehydrogenase. Endocrinology 148:5072-5080 (Pubitemid 47481507)
26. Lavery GG, Walker EA, Tiganescu A, Ride JP, Shackleton CH, Tomlinson JW, Connell JM, Ray DW, Biason-Lauber A, Malunowicz EM, Arlt W, Stewart PM 2008 Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J Clin Endocrinol Metab 93:3827-3832
27. Lawson AJ, Walker EA, Lavery GG, Bujalska IJ, Hughes B, Arlt W, Stewart PM, Ride JP 2011 Cortisone-reductase deficiency associated with heterozygous mutations in 11β-hydroxysteroid dehydrogenase type 1. Proc Natl Acad Sci USA 108:4111-4116
28. Semjonous NM, Sherlock M, Jeyasuria P, Parker KL, Walker EA, Stewart PM, Lavery GG 2011 Hexose-6-phosphate dehydrogenase contributes to skeletal muscle homeostasis independent of 11β-hydroxysteroid dehydrogenase type 1. Endocrinology 152:93-102
29. Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, Shelton KD, Lindner J, Cherrington AD, Magnuson MA 1999 Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic β cell-specific gene knock-outs using Cre recombinase. J Biol Chem 274:305-315 (Pubitemid 29035064)
30. Chapman KE, Coutinho AE, Gray M, Gilmour JS, Savill JS, Seckl JR 2009 The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in the inflammatory response. Mol Cell Endocrinol 301:123-131
31. Gilmour JS, Coutinho AE, Cailhier JF, Man TY, Clay M, Thomas G, Harris HJ, Mullins JJ, Seckl JR, Savill JS, Chapman KE 2006 Local amplification of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1 promotes macrophage phagocytosis of apoptotic leukocytes. J Immunol 176:7605-7611 (Pubitemid 43853055)
32. Hadoke PW, Lindsay RS, Seckl JR, Walker BR, Kenyon CJ 2006 Altered vascular contractility in adult female rats with hypertension programmed by prenatal glucocorticoid exposure. J Endocrinol 188:435-442
33. Draper N, Stewart PM 2005 11β-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol 186:251-271 (Pubitemid 41167396)
34. Brereton PS, van Driel RR, Suhaimi Fb, Koyama K, Dilley R, Krozowski Z 2001 Light and electron microscopy localization of the 11β-hydroxysteroid dehydrogenase type I enzyme in the rat. Endocrinology 142:1644-1651
35. Gomez-Sanchez EP, Romero DG, de Rodriguez AF, Warden MP, Krozowski Z, Gomez-Sanchez CE 2008 Hexose-6-phosphate dehydrogenase and 11β- hydroxysteroid dehydrogenase-1 tissue distribution in the rat. Endocrinology 149:525-533 (Pubitemid 351159346)
36. Brem AS, Bina RB, King T, Chobanian MC, Morris DJ 1997 Influence of dietary sodium on the renal isoforms of 11 β-hydroxysteroid dehydrogenase. Proc Soc Exp Biol Med 214:340-345
37. Gong R, Morris DJ, Brem AS 2008 Human renal 11β-hydroxysteroid dehydrogenase 1 functions and co-localizes with COX-2. Life Sci 82:631-637
38. Ricketts ML, Verhaeg JM, Bujalska I, Howie AJ, Rainey WE, Stewart PM 1998 Immunohistochemical localization of type 1 11β-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab 83:1325-1335 (Pubitemid 28496416)
39. Carter RN, Paterson JM, Tworowska U, Stenvers DJ, Mullins JJ, Seckl JR, Holmes MC 2009 Hypothalamic-pituitary-adrenal axis abnormalities in response to deletion of 11β-HSD1 is strain-dependent. J Neuroendocrinol 21:879-887
40. Densmore VS, Morton NM, Mullins JJ, Seckl JR 2006 11β-Hydroxysteroid dehydrogenase type 1 induction in the arcuate nucleus by high-fat feeding: a novel constraint to hyperphagia? Endocrinology 147:4486-4495 (Pubitemid 44268400)
41. Morgan SA, Sherlock M, Gathercole LL, Lavery GG, Lenaghan C, Bujalska IJ, Laber D, Yu A, Convey G, Mayers R, Hegyi K, Sethi JK, Stewart PM, Smith DM, Tomlinson JW 2009 11β-Hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes 58:2506-2515
42. Swali A, Walker EA, Lavery GG, Tomlinson JW, Stewart PM 2008 11β-Hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets. Diabetologia 51:2003-2011
43. Morton NM 2010 Obesity and corticosteroids: 11β-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol Cell Endocrinol 316:154-164
44. Wyrwoll CS, Holmes MC, Seckl JR 2011 11β-Hydroxysteroid dehydrogenases and the brain: from zero to hero, a decade of progress. Front Neuroendocrinol 32:265-286
45. Morton NM, Seckl JR 2008 11β-Hydroxysteroid dehydrogenase type 1 and obesity. Front Horm Res 36:146-164
46. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH 1999 Cortisol metabolism in human obesity: impaired cortisone->cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 84:1022-1027 (Pubitemid 29138237)
47. Li G, Hernandez-Ono A, Crooke RM, Graham MJ, Ginsberg HN 2011 Effects of antisense-mediated inhibition of 11β-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism. J Lipid Res 52:971-981
48. Alberts P, Engblom L, Edling N, Forsgren M, Klingström G, Larsson C, Rönquist-Nii Y, Ohman B, Abrahmsén L 2002 Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 45:1528-1532 (Pubitemid 35352046)
49. Liu J, Wang L, Zhang A, Di W, Zhang X, Wu L, Yu J, Zha J, Lv S, Cheng P, Hu M, Li Y, Qi H, Ding G, Zhong Y 2011 Adipose tissue-targeted 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against diet-induced obesity. Endocr J 58:199-209
50. Postic C, Girard J 2008 The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab 34:643-648
51. Berthiaume M, Laplante M, Festuccia WT, Cianflone K, Turcotte LP, Joanisse DR, Olivecrona G, Thieringer R, Deshaies Y 2007 11β-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues. Am J Physiol Endocrinol Metab 293:E1045-E1052 (Pubitemid 47535836)
52. Berthiaume M, Laplante M, Festuccia W, Gélinas Y, Poulin S, Lalonde J, Joanisse DR, Thieringer R, Deshaies Y 2007 Depot-specific modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11β-hydroxysteroid dehydrogenase type 1. Endocrinology 148:2391-2397 (Pubitemid 46997032)
53. Berthiaume M, Laplante M, Festuccia WT, Berger JP, Thieringer R, Deshaies Y 2010 Preliminary report: pharmacologic 11β-hydroxysteroid dehydrogenase type 1 inhibition increases hepatic fat oxidation in vivo and expression of related genes in rats fed an obesogenic diet. Metabolism 59:114-117
54. Tomlinson JW, Sherlock M, Hughes B, Hughes SV, Kilvington F, Bartlett W, Courtney R, Rejto P, Carley W, Stewart PM 2007 Inhibition of 11β-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J Clin Endocrinol Metab 92:857-864 (Pubitemid 46465655)